AstraZeneca Pharma soars on receiving permission from DCGI for Dapagliflozin Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Astrazeneca Pharma India is currently trading at Rs. 3816.10, up by 46.70 points or 1.24% from its previous closing of Rs. 3769.40 on the BSE.
The scrip opened at Rs. 3805.05 and has touched a high and low of Rs. 3882.70 and Rs. 3800.00 respectively. So far 717 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3882.70 on 25-Jul-2023 and a 52 week low of Rs. 2939.10 on 14-Oct-2022.
Last one week high and low of the scrip stood at Rs. 3882.70 and Rs. 3752.75 respectively. The current market cap of the company is Rs. 9531.13 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 4.59% and 20.41% respectively.
AstraZeneca Pharma India has received Permission to Import Pharmaceutical Formulations of New Drug for Sale or for Distribution in Form CT-20 (Marketing Authorisation - Additional Indication) from the Drugs Controller General of India (DCGI) for Dapagliflozin Tablets 10 mg. Through this approval, Dapagliflozin Tablets 10mg is indicated for the treatment of heart failure in adults. The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg in India for the specified indication, subject to the receipt of related statutory approvals and licenses.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
